STAT

SEPTEMBER 14, 2023

adult population, there has been no significant progress in understanding its causes, prevention, or treatment. On the research side, the U.S. government rapidly anticipated and tried to blunt the force of this national calamity by investing in basic and clinical research. Read the rest…

Patient Care 145

Patient Care 145

PhRMA

AUGUST 16, 2022

Innovative biopharmaceutical research companies have been dedicated to fighting COVID-19 for over two years. Since the start of the pandemic, America’s biopharmaceutical companies have worked around the clock to research, develop and manufacture treatments and vaccines to fight COVID-19.

Vaccines 196

Vaccines 196

STAT

MARCH 5, 2024

is making progress in reducing the public health consequences of air pollutants and fine particulate matter. Researchers found an overall drop from 2010 and 2019 in death and disease linked to nitrogen dioxide (NO2), an air pollutant produced from fossil fuel burning, and fine particulate matter (PM2.5) pollution.

134

134

STAT

SEPTEMBER 8, 2023

But in recent years, progress in the world of ALS research and drug development has come to embody a conundrum with far broader implications: The balance between moving aggressively on promising new cures and guarding against false hope. A diagnosis of ALS has long been seen as a death sentence. Read the rest…

FDA 145

FDA 145

Hospital Pharmacy Europe

APRIL 15, 2024

The glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide, commonly used to treat type 2 diabetes, may slow the progression of Parkinson’s disease symptoms, research suggests. A larger phase three trial of exenatide, led by UK researchers, is due to report later this year.

Hospitals 59

Hospitals 59

STAT

NOVEMBER 15, 2023

That’s because Sheybani has been unable to hire a postdoctoral researcher since starting her lab in 2021. Academia is in the midst of an unprecedented exodus of life science researchers, many of whom are leaving for lucrative jobs in the private sector. But in each case the candidate opted for a job at a biotech company.

145

145

Outsourcing Pharma

MARCH 1, 2024

In the dynamic realm of clinical trials, where innovation and patient care intersect, Advarra believes it stands as a beacon of progress, continually revolutionizing how medical research is conducted.

Patient Care 71

Patient Care 71

STAT

NOVEMBER 13, 2023

is nearly six years shorter than that of women, according to new research published on Monday in JAMA Internal Medicine. in 2022 — undoing over two decades of progress. in 2022 — undoing over two decades of progress. The life expectancy of men in the U.S. years in 2019 to 77 in 2020 and 76.1 and China (78.2)

145

145

STAT

SEPTEMBER 20, 2023

Researchers say they’ve been able to measure recovery from treatment-resistant depression through brain scans — a crucial step toward quantifying the impact of therapies on a condition whose progress is notoriously difficult to measure objectively. And that’s thanks to generative AI , they say.

130

130

European Pharmaceutical Review

JANUARY 17, 2024

The small molecule heart failure drug acoramidis has potential in slowing or stopping the progression of transthyretin amyloid cardiomyopathy (ATTR-CM), according to study data published in the New England Journal of Medicine. The post Novel heart failure drug could halt disease progression appeared first on European Pharmaceutical Review.

FDA 78

FDA 78

Fierce Pharma

JULY 5, 2023

Despite political tensions between Washington and Beijing, foreign pharmaceutical investments are progressing in China. | In a deal that could be worth up to $1 billion, Massachusetts-based Moderna inked a memorandum of understanding, plus a land collaboration agreement, to research, develop and manufacture mRNA medicines in China.

106

106

Outsourcing Pharma

MARCH 1, 2024

In the dynamic realm of clinical trials, where innovation and patient care intersect, Medidata believes it stands as a beacon of progress, continually revolutionizing how medical research is conducted.

Patient Care 59

Patient Care 59

STAT

APRIL 29, 2024

Daiichi Sankyo and AstraZeneca said their targeted cancer drug Enhertu showed a  statistically significant and clinically meaningful slowing  of tumor progression in a randomized, Phase 3 study involving patients with hormone-positive, HER2-low metastatic breast cancer.

Immunization 101

Immunization FDA Vaccines 101

Pharmacy Times

DECEMBER 13, 2023

There is progress being made regarding research on immunotherapies and the mutation, which adversely affects a higher number of patients in this population.

65

65

STAT

MARCH 8, 2024

This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment? This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

128

128

European Pharmaceutical Review

DECEMBER 7, 2023

People with type 1 diabetes in the trial who were given the drug required significantly less insulin for treatment,” stated Professor Thomas Kay, Director of the St Vincent’s Institute of Medical Research in Australia.  Participants remained on their prescribed insulin medication throughout the study.

Immunization 103

Immunization 103

STAT

NOVEMBER 7, 2023

The officials, including the Food and Drug Administration’s second-in-command Janet Woodcock, acknowledged the drug industry’s persistent lack of interest in collaborating on clinical trials, the ways hypercompetition pervades academic research and slows progress, and biotech investors taking the wrong lessons from pandemic.

Vaccines 127

Vaccines FDA 127

IDStewardship

JUNE 5, 2023

They highlight the significance of policy development, surveillance systems, and the responsibility of individuals, healthcare professionals, and policymakers in curbing the progression of resistance. In this article the artificial intelligence program ChatGPT is interviewed about antimicrobial stewardship. Gauthier, Pharm.D.,

Vaccines 234

Vaccines Hospitals Patient Care 234

STAT

OCTOBER 13, 2022

Research often proceeds in a logical progression, new studies building upon a detailed understanding of the underlying processes revealed by earlier work.

136

136

STAT

JUNE 4, 2023

CHICAGO – An experimental drug dramatically slowed the growth of glioma, a type of brain cancer, if the tumor carried a specific type of genetic alteration, researchers said Sunday, potentially sparing patients exposure to radiation and chemotherapy. Progression took 11.1 months for those who took a placebo, and increased to 27.7

Chemotherapy 108

Chemotherapy 108

STAT

APRIL 19, 2023

She has difficulty maintaining her balance at times in addition to progressive vision loss, but she claims HHMI refused to provide accommodations that would enable her to continue her research, and pushed her to leave.

135

135

STAT

APRIL 29, 2024

Physicians involved with MorphoSys’ completed Phase 3 study have reported multiple cases of palebresib-treated patients who rapidly progressed from myelofibrosis, a cancer affecting the bone marrow, to acute myeloid leukemia, a more aggressive and deadlier type of blood cancer, according to two people with knowledge of the cases.

112

112

STAT

SEPTEMBER 6, 2022

In a long-overdue move, the federal Office of Science and Technology Policy has issued guidance on making federally supported research and publications available to all without delay or embargo. Even with immediate open access to research results, however, people with disabilities face unique barriers to information access.

126

126

European Pharmaceutical Review

NOVEMBER 28, 2023

SpringWorks Therapeutics’ Ogsiveo (nirogacestat) tablets are authorised for adults with progressing desmoid tumours who require systemic treatment. According to the FDA, this clinical trial evaluated 142 adult patients with progressing desmoid tumours not suitable to surgery.

Labelling 82

Labelling FDA 82

STAT

OCTOBER 23, 2023

All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease. MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments.

127

127

Fierce Pharma

NOVEMBER 1, 2023

In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky talks with the study lead, Reisa Sperling, M.D., to learn more.

72

72

Hospital Pharmacy Europe

JULY 18, 2023

Donanemab has been found to slow the progression of early symptomatic Alzheimer’s disease after 76 weeks of treatment, according to the findings of a phase 3 randomised trial. Nearly half of those given the drug showed no signs of disease progression after 12 months. women) with a mean age of 73.0 years were recruited.

Hospitals 98

Hospitals 98

European Pharmaceutical Review

DECEMBER 5, 2023

The programme is the EU’s key funding initiative for research and innovation with a budget of €95.5 Research challenges such as digital transformation and health are examples of what those involved in the programme will be able to work together to overcome. billion for 2021-27.

93

93

STAT

JUNE 4, 2023

CHICAGO — An antibody that delivers chemotherapy directly to tumor cells extended the lives of women with a form of advanced ovarian cancer in a large study, researchers reported Sunday. The drug also shrank tumors and delayed disease progression. The drug, called Elahere, is made by the biotech company Immunogen.

Chemotherapy 133

Chemotherapy 133

Hospital Pharmacy Europe

FEBRUARY 29, 2024

The ATOMIC-Meso trial is the continuation of 20 years of research at Barts Cancer Institute at Queen Mary University of London, that began with the discovery that malignant mesothelioma cells lack the argininosuccinate synthetase 1 (ASS1) protein, which enables cells to manufacture their own arginine. mg/ m2) or placebo.

Chemotherapy 52

Chemotherapy Immunization Hospitals 52

European Pharmaceutical Review

MARCH 15, 2024

Researchers have proposed an advanced analytical technology that can rapidly classify medical cannabis plants at production sites. However, using a hyperspectral camera enabled the researchers “to differentiate between plant chemotypes using a much simpler system”.

76

76

European Pharmaceutical Review

NOVEMBER 7, 2022

Results from the EMPA-KIDNEY Phase III clinical trial announced at the American Society of Nephrology (ASN)’s Kidney Week 2022, demonstrated Jardiance ® (empagliflozin) reduced the risk of kidney disease progression or cardiovascular death by 28 percent versus placebo in adults with chronic kidney disease (CKD). to 0.95, p=0.0025.

78

78

Fierce Pharma

OCTOBER 19, 2023

The first biologic to win approval to treat moderate to severe psoriasis was Astellas’ now-discontinued Amevive (alefacept) in 2003, paving the way for significant progress in the disease space. | The company hopes that its study model can set an example for inclusive research.

62

62

European Pharmaceutical Review

FEBRUARY 15, 2024

While the disease can usually be treated with chemotherapy, it is not often capable of stopping progression of the disease. Therefore, the findings from the clinical trial are “significant”, according to researchers. The research has been published in JAMA Oncology. months and quadrupled the survival at 36 months.

Chemotherapy 90

Chemotherapy 90

Pharmaceutical Technology

JUNE 13, 2023

The combination therapy is intended to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in adult patients, after recurrence or progression on or after an endocrine-based regimen. AstraZeneca stated that its NDA is being reviewed under Project Orbis.

FDA 98

FDA 98

European Pharmaceutical Review

DECEMBER 22, 2023

Tusamitamab ravtansine as a monotherapy did not meet its dual primary endpoint of progression-free survival (PFS) compared to docetaxel” Sanofi said that an Independent Data Monitoring Committee found that tusamitamab ravtansine as a monotherapy did not meet its dual primary endpoint of progression-free survival (PFS) compared to docetaxel.

Labelling 101

Labelling 101

Hospital Pharmacy Europe

MARCH 6, 2023

In the current study, researchers built upon the success of TRITON2. In the current study, researchers built upon the success of TRITON2. They set the primary outcome as the median duration of imaging-based progression-free survival according to independent review. years were randomised to rucaparib (270) or control.

Hospitals 98

Hospitals 98